SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer—Overall survival (OS) analysis.

Sylvain Dureau,Francesco Ricci,Marie Alt,Delphine Loirat,Marie Paule Sablin,Maud Kamal,Ivan Bièche,Sebastien Armanet,Jean-Pierre Delord,Anthony Gonçalves,Celine Gavoille,Coraline Dubot,Nicolas Isambert,Mario Campone,Olivier Tredan,Miguelle Marous,Aurélien Latouche,L. Belin,Christophe Le Tourneau

SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer—Overall survival (OS) analysis.

2017

Sylvain Dureau
Francesco Ricci
Marie Alt
Delphine Loirat
Marie Paule Sablin
Maud Kamal
Ivan Bièche
Sebastien Armanet
Jean-Pierre Delord
Anthony Gonçalves
Celine Gavoille
Coraline Dubot
Nicolas Isambert
Mario Campone
Olivier Tredan
Miguelle Marous
Aurélien Latouche
L. Belin
Christophe Le Tourneau

11515Background: The SHIVA trial is a multicentric randomized phase II trial comparing molecularly targeted therapy among 11 drugs based on tumor molecular profiling versus conventional therapy in ...

Keywords:

Targeted therapy
Oncology
Pathology
Refractory cancer
Medicine
Internal medicine
in patient
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations